伴有外置脑室引流管的葡萄球菌性脑室炎神经重症监护患者脑脊液和血浆中静脉注射利奈唑胺的药代动力学
Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.
作者信息
Beer Ronny, Engelhardt Klaus W, Pfausler Bettina, Broessner Gregor, Helbok Raimund, Lackner Peter, Brenneis Christian, Kaehler Stefan T, Georgopoulos Apostolos, Schmutzhard Erich
机构信息
Innsbruck Medical University, Clinical Department of Neurology, Neurological Intensive Care Unit, Anichstrasse 35, 6020 Innsbruck, Austria.
出版信息
Antimicrob Agents Chemother. 2007 Jan;51(1):379-82. doi: 10.1128/AAC.00515-06. Epub 2006 Oct 16.
Abstract
The pharmacokinetic profile of linezolid in cerebrospinal fluid (CSF) in five neurointensive care patients with staphylococcal ventriculitis was studied. The mean area under concentration-time curve (+/- standard deviation) was 63 +/- 18.9 mg x h/liter, with a CSF-to-plasma ratio of 0.8 +/- 0.3. Times above MIC in CSF were 99.8% and 57.2% for pathogens with MICs of 2 mg/liter and 4 mg/liter, respectively.
摘要
对5例患有葡萄球菌性脑室炎的神经重症监护患者脑脊液中线粒体的药代动力学特征进行了研究。浓度-时间曲线下的平均面积（±标准差）为63±18.9mg·h/升，脑脊液与血浆的比率为0.8±0.3。对于最低抑菌浓度（MIC）为2mg/升和4mg/升的病原体，脑脊液中高于MIC的时间分别为99.8%和57.2%。
相似文献
1
Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.
Antimicrob Agents Chemother. 2007 Jan;51(1):379-82. doi: 10.1128/AAC.00515-06. Epub 2006 Oct 16.
2
Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis.
Ann Pharmacother. 2006 Jul-Aug;40(7-8):1451-5. doi: 10.1345/aph.1H029. Epub 2006 Jun 13.
3
Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.
Antimicrob Agents Chemother. 2006 Dec;50(12):3971-6. doi: 10.1128/AAC.00051-06. Epub 2006 Sep 18.
4
Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
Scand J Infect Dis. 2011 Sep;43(9):721-7. doi: 10.3109/00365548.2011.582140. Epub 2011 May 17.
5
Linezolid cerebrospinal fluid concentration in central nervous system infection.
J Chemother. 2007 Feb;19(1):90-3. doi: 10.1179/joc.2007.19.1.90.
6
Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.
J Infect. 2005 Apr;50(3):252-7. doi: 10.1016/j.jinf.2004.04.002.
7
Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
Int J Antimicrob Agents. 2014 Nov;44(5):409-15. doi: 10.1016/j.ijantimicag.2014.07.001. Epub 2014 Aug 20.
8
Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy.
J Neurosurg. 2003 May;98(5):1040-4. doi: 10.3171/jns.2003.98.5.1040.
9
Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
Int J Antimicrob Agents. 2013 Oct;42(4):329-34. doi: 10.1016/j.ijantimicag.2013.06.015. Epub 2013 Aug 26.
10
Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
Int J Antimicrob Agents. 2011 Oct;38(4):296-300. doi: 10.1016/j.ijantimicag.2011.05.007. Epub 2011 Jul 8.
引用本文的文献
1
Treatment Options for Nosocomial Ventriculitis/Meningitis: A Case Report and Review of the Literature.
Pathogens. 2024 Dec 26;14(1):3. doi: 10.3390/pathogens14010003.
2
Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.
J Med Chem. 2025 Feb 13;68(3):2779-2803. doi: 10.1021/acs.jmedchem.4c02086. Epub 2025 Jan 21.
3
Linezolid brain penetration in neurointensive care patients.
J Antimicrob Chemother. 2024 Mar 1;79(3):669-677. doi: 10.1093/jac/dkae025.
4
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.
Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058.
5
Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis.
Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5.
6
Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis.
Heliyon. 2023 Nov 7;9(11):e21962. doi: 10.1016/j.heliyon.2023.e21962. eCollection 2023 Nov.
7
German guidelines on community-acquired acute bacterial meningitis in adults.
Neurol Res Pract. 2023 Aug 31;5(1):44. doi: 10.1186/s42466-023-00264-6.
8
Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis.
Antibiotics (Basel). 2023 Apr 3;12(4):702. doi: 10.3390/antibiotics12040702.
9
Dynamic F-Pretomanid PET imaging in animal models of TB meningitis and human studies.
Nat Commun. 2022 Dec 29;13(1):7974. doi: 10.1038/s41467-022-35730-3.
10
Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.
BMC Pharmacol Toxicol. 2022 Nov 30;23(1):89. doi: 10.1186/s40360-022-00628-9.
本文引用的文献
1
Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.
Antimicrob Agents Chemother. 2006 Dec;50(12):3971-6. doi: 10.1128/AAC.00051-06. Epub 2006 Sep 18.
2
Optimizing blood pressure in neurological emergencies.
Neurocrit Care. 2004;1(3):287-99. doi: 10.1385/NCC:1:3:287.
3
Clinical experience with linezolid for the treatment of central nervous system infections.
Eur J Neurol. 2005 Jul;12(7):536-42. doi: 10.1111/j.1468-1331.2005.01001.x.
4
Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration.
J Antimicrob Chemother. 2005 Jul;56(1):172-9. doi: 10.1093/jac/dki133. Epub 2005 May 19.
5
Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples.
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 25;796(1):155-64. doi: 10.1016/j.jchromb.2003.08.019.
6
Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans.
Antimicrob Agents Chemother. 2003 Oct;47(10):3099-103. doi: 10.1128/AAC.47.10.3099-3103.2003.
7
Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy.
J Neurosurg. 2003 May;98(5):1040-4. doi: 10.3171/jns.2003.98.5.1040.
8
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii17-25. doi: 10.1093/jac/dkg248.
9
The impact of methicillin-resistant Staphylococcus aureus in a neurosurgical unit: a growing problem.
J Neurosurg. 2003 Jan;98(1):8-13. doi: 10.3171/jns.2003.98.1.0008.
10
In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Antimicrob Agents Chemother. 2002 Nov;46(11):3484-9. doi: 10.1128/AAC.46.11.3484-3489.2002.
Zotero 插件